Oral bioavailability is a constant challenge for developers of new chemical entities. Low solubility and permeability often reduce the fraction of an orally administered drug absorbed in the bloodstream. Increasing the dose to have adequate circulating drug may not always be feasible. Drug developers need ways to improve the bioavailability of their molecules. PPS’ newly expanded Bioavailability Enhancement Platform is an enabling technology for the advancement of promising drug candidates into clinical development and beyond, making it a key part of PPS' focus on improving patients’ lives.
